drugset / Trial / NCT05579730
Evaluation of Brimonidine Tartrate/Ketotifen Fumarate Combination for the Treatment of Allergic Conjunctivitis
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy of Combo (Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution) compared to its individual components and vehicle in a population of subjects with allergic conjunctivitis:
Timeline
- Start
- 2022-10-12
- Primary completion
- 2023-07-22
- Completion
- 2023-07-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Brimonidine | Unknown | 0.025 % | — |
| Subject | Ketotifen | Small molecule | 0.035 % | — |